Scarica l'app Stockscreener
692.58
1.52%
-10.68
Dopo l'orario di chiusura:
693.30
0.72
+0.10%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché REGN Giù?
Forum
Previsione
Precedente Chiudi:
$703.26
Aprire:
$705.11
Volume 24 ore:
604.19K
Relative Volume:
0.56
Capitalizzazione di mercato:
$72.79B
Reddito:
$14.25B
Utile/perdita netta:
$4.58B
Rapporto P/E:
16.58
EPS:
41.7701
Flusso di cassa netto:
$3.88B
1 W Prestazione:
-6.66%
1M Prestazione:
+5.33%
6M Prestazione:
+33.81%
1 anno Prestazione:
-12.11%
Intervallo 1D:
$691.86
$711.15
Intervallo di 1 settimana:
$691.86
$744.23
Portata 52W:
$476.49
$791.49
Regeneron Pharmaceuticals Inc Stock (REGN) Company Profile
Nome
Regeneron Pharmaceuticals Inc
Settore
Industria
Telefono
(914) 847-7000
Indirizzo
777 OLD SAW MILL RIVER ROAD, TARRYTOWN, NY
Confronta REGN con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
REGN
Regeneron Pharmaceuticals Inc
|
692.58 | 73.91B | 14.25B | 4.58B | 3.88B | 41.77 |
|
VRTX
Vertex Pharmaceuticals Inc
|
437.01 | 112.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
415.21 | 56.81B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
889.41 | 55.46B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
194.17 | 41.92B | 447.02M | -1.18B | -906.14M | -6.1812 |
Regeneron Pharmaceuticals Inc Stock (REGN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-03 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2025-11-24 | Iniziato | HSBC Securities | Buy |
| 2025-11-24 | Ripresa | Truist | Buy |
| 2025-11-13 | Iniziato | Scotiabank | Sector Perform |
| 2025-08-14 | Iniziato | Rothschild & Co Redburn | Buy |
| 2025-06-30 | Downgrade | Argus | Buy → Hold |
| 2025-05-30 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-05-30 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2025-05-14 | Aggiornamento | Citigroup | Neutral → Buy |
| 2025-04-22 | Ripresa | Cantor Fitzgerald | Overweight |
| 2025-02-05 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2025-01-16 | Downgrade | UBS | Buy → Neutral |
| 2024-12-10 | Ripresa | BofA Securities | Underperform |
| 2024-11-15 | Iniziato | Wolfe Research | Outperform |
| 2024-11-14 | Iniziato | Citigroup | Neutral |
| 2024-09-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2024-03-12 | Iniziato | Bernstein | Outperform |
| 2024-01-12 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-11-09 | Iniziato | Deutsche Bank | Hold |
| 2023-11-03 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2023-08-21 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2023-08-21 | Reiterato | Oppenheimer | Perform |
| 2023-06-28 | Downgrade | Canaccord Genuity | Buy → Hold |
| 2023-03-27 | Aggiornamento | SVB Securities | Market Perform → Outperform |
| 2023-03-24 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-03-23 | Aggiornamento | Raymond James | Underperform → Mkt Perform |
| 2023-01-30 | Aggiornamento | Cowen | Market Perform → Outperform |
| 2023-01-20 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2022-10-26 | Downgrade | Raymond James | Mkt Perform → Underperform |
| 2022-10-17 | Downgrade | Evercore ISI | Outperform → In-line |
| 2022-09-09 | Aggiornamento | Jefferies | Underperform → Hold |
| 2022-09-09 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2022-07-25 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2022-07-13 | Iniziato | Cantor Fitzgerald | Neutral |
| 2022-06-06 | Iniziato | Jefferies | Underperform |
| 2022-05-23 | Iniziato | SVB Leerink | Outperform |
| 2022-01-05 | Downgrade | BofA Securities | Neutral → Underperform |
| 2022-01-03 | Aggiornamento | Bernstein | Mkt Perform → Outperform |
| 2021-12-15 | Downgrade | Bernstein | Outperform → Mkt Perform |
| 2021-12-09 | Ripresa | Wells Fargo | Overweight |
| 2021-12-07 | Ripresa | Cowen | Market Perform |
| 2021-12-06 | Iniziato | Goldman | Buy |
| 2021-11-19 | Ripresa | BMO Capital Markets | Outperform |
| 2021-11-05 | Downgrade | The Benchmark Company | Buy → Hold |
| 2021-06-29 | Iniziato | H.C. Wainwright | Buy |
| 2021-01-25 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2021-01-13 | Aggiornamento | The Benchmark Company | Hold → Buy |
| 2021-01-08 | Aggiornamento | Citigroup | Neutral → Buy |
| 2020-10-05 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2020-08-20 | Downgrade | The Benchmark Company | Buy → Hold |
| 2020-07-09 | Aggiornamento | SunTrust | Hold → Buy |
| 2020-05-26 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2020-04-28 | Downgrade | Citigroup | Buy → Neutral |
| 2020-04-17 | Aggiornamento | The Benchmark Company | Hold → Buy |
| 2020-04-08 | Iniziato | The Benchmark Company | Hold |
| 2020-03-31 | Iniziato | Wolfe Research | Peer Perform |
| 2020-02-27 | Iniziato | Barclays | Overweight |
| 2020-02-26 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2020-02-26 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2020-02-25 | Aggiornamento | Jefferies | Hold → Buy |
| 2020-02-11 | Aggiornamento | Argus | Hold → Buy |
| 2019-12-24 | Iniziato | Raymond James | Mkt Perform |
| 2019-12-16 | Downgrade | Evercore ISI | Outperform → In-line |
| 2019-12-13 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2019-11-12 | Iniziato | SunTrust | Hold |
| 2019-11-07 | Aggiornamento | Citigroup | Neutral → Buy |
| 2019-10-17 | Ripresa | BofA/Merrill | Neutral |
| 2019-09-23 | Aggiornamento | Guggenheim | Neutral → Buy |
Mostra tutto
Regeneron Pharmaceuticals Inc Borsa (REGN) Ultime notizie
Regeneron Climbs Back After a Year of Regulatory, Manufacturing Misery - BioSpace
Regeneron (REGN): Revisiting Valuation After a Short-Term Pullback and Longer-Term Shareholder Weakness - simplywall.st
Kymera Keeps Rising With More Positive Dupixent-In-A-Pill Data - Citeline News & Insights
Regeneron Pharmaceuticals' Upcoming Melanoma Data Likely to Look Competitive, RBC Says - marketscreener.com
ASH takeaways: Regeneron unveils new data on blood cancer drugs, touts hematology pipeline - Medical Marketing and Media
Regeneron Pharmaceuticals Inc. stock underperforms Monday when compared to competitors - MSN
Here's Why You Should Retain OPKO Health Stock in Your Portfolio Now - TradingView
Ossiam Sells 22,234 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals Stock Slides 11% With A 8-Day Losing Spree - Trefis
Regeneron Pharmaceuticals: Is Wall Street Finally Paying Attention (NASDAQ:REGN) - Seeking Alpha
Regeneron's (REGN) Recovery and Dupixent Strength Support BMO's Outperform Rating - Finviz
Regeneron’s (REGN) recovery and Dupixent strength support BMO’s outperform rating - MSN
Regeneron’s (REGN) Recovery and Dupixent Strength Support BMO’s Outperform Rating - Insider Monkey
Why Is Kymera Therapeutics Stock Skyrocketing Monday?Kymera Therapeutics (NASDAQ:KYMR) - Benzinga
Natixis Purchases 2,751 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Tessera Therapeutics Showcases New Preclinical Data Demonstrating Progress of In Vivo Programs for Sickle Cell Disease and T Cell Therapies at the 67th American Society of Hematology Annual Meeting - GlobeNewswire Inc.
Anti-VEGF Market Growth Outlook: USD 41.3 Billion by 2035 With - openPR.com
California Public Employees Retirement System Sells 158,734 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
14 Best US Stocks to Buy for Long Term - Insider Monkey
Regeneron (REGN) Showcases Promising Trial Data for Lynozyfic in Multiple Myeloma - GuruFocus
Regeneron Reports Promising Results from LINKER-MM4 Trial of Lynozyfic™ for Newly Diagnosed Multiple Myeloma - Quiver Quantitative
Lynozyfic™ (linvoseltamab) Monotherapy in Newly Diagnosed Multiple Myeloma (NDMM) Shows Impressive Responses, Supporting Rationale as a Potential Foundation in Frontline Treatment - The Manila Times
Federated Hermes Inc. Acquires 204,045 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Understanding Momentum Shifts in (REGN) - news.stocktradersdaily.com
Can Regeneron Pharmaceuticals Stock Recover If Markets Fall? - Trefis
Does Regeneron’s Choppy 2025 Share Price Reflect Its Long Term Growth Potential? - Yahoo Finance
Regeneron's experimental therapy combo effective in untreated cancer patients - Reuters
Marshall Wace LLP Has $125.95 Million Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by Panagora Asset Management Inc. - MarketBeat
First Trust Advisors LP Increases Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Baird Financial Group Inc. Grows Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by Amundi - MarketBeat
Canaccord Genuity Group Forecasts Strong Price Appreciation for Regeneron Pharmaceuticals (NASDAQ:REGN) Stock - MarketBeat
Is Regeneron Still Attractive After Recent Pipeline Milestones and Valuation Upside Signals? - simplywall.st
BMO Capital Markets Issues Positive Forecast for Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Price - MarketBeat
Can Regeneron Pharmaceuticals Inc. stock maintain growth trajectoryJuly 2025 Retail & Free Safe Entry Trade Signal Reports - Newser
Regeneron Pharmaceuticals, Inc. $REGN Shares Bought by Guggenheim Capital LLC - MarketBeat
Invesco Ltd. Grows Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Why Regeneron Pharmaceuticals Inc. (RGO) stock is listed among top recommendationsOptions Play & Community Driven Trade Alerts - Newser
Dodge & Cox Acquires 1,502,198 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals, Inc. $REGN Holdings Lowered by Epoch Investment Partners Inc. - MarketBeat
Will Regeneron Pharmaceuticals Inc. (RGO) stock profit from fiscal stimulus2025 Retail Activity & Daily Momentum Trading Reports - Newser
How Regeneron Pharmaceuticals Inc. (RGO) stock responds to job market shiftsJuly 2025 Trends & Weekly Setup with ROI Potential - Newser
Can Regeneron Pharmaceuticals Inc. (RGO) stock sustain institutional flowsJuly 2025 Update & High Accuracy Trade Alerts - Newser
Regeneron Pharmaceuticals, Inc. (REGN): A Bull Case Theory - Insider Monkey
Citi Healthcare In Brief: Launch Trajectories Under Scrutiny - Citeline News & Insights
Can Regeneron Pharmaceuticals Inc. stock sustain institutional interestMarket Volume Report & Weekly Top Stock Performers List - Newser
Market Whales and Their Recent Bets on REGN Options - Benzinga
REGN: BMO Capital Raises Price Target and Maintains Outperform R - GuruFocus
BMO Capital raises Regeneron Pharma stock price target to $850 on Dupixent growth - Investing.com
Regeneron Pharmaceuticals (NASDAQ:REGN) Rating Lowered to "Equal Weight" at Morgan Stanley - MarketBeat
Regeneron Pharmaceuticals Inc Azioni (REGN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.44%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):